Physician profile
Mark A Dirnberger
NPI 1841366465
$8,066.03
in general payments reported to CMS, 2019-2025
58 companies · $619 in 2025
The $619 reported for 2025 was more than what 80% of Neuromusculoskeletal Medicine & Omm providers received nationally (typical 2025 total: $119).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,148 · 2020: $794 · 2021: $2,301 · 2022: $1,255 · 2023: $1,009 · 2024: $939 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,247.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,116.15 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $892.47 | 2019-2024 | Ztlido |
| Collegium Pharmaceutical, INC. | $564.30 | 2019-2025 | Xtampza |
| Abbvie INC. | $398.25 | 2021-2025 | |
| Horizon Therapeutics Plc | $379.74 | 2019-2022 | |
| Abbott Laboratories | $269.96 | 2019-2025 | Proclaim, Eterna |
| Amgen INC. | $224.94 | 2020-2022 | |
| Nevro Corp. | $209.05 | 2019-2021 | |
| Boston Scientific Corporation | $192.69 | 2019-2022 | |
| Averitas Pharma INC. | $172.90 | 2024-2025 | Qutenza |
| Zyla Life Sciences, INC. | $154.84 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $125.98 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.69 | 2022 | |
| Azurity Pharmaceuticals, INC. | $121.68 | 2024-2025 | Horizant |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $120.45 | 2021-2022 | |
| Pfizer INC. | $115.83 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $105.36 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $96.70 | 2024-2025 | |
| Almatica Pharma LLC | $85.05 | 2022-2023 | Gralise |
| Si-Bone, INC. | $80.44 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $77.28 | 2021-2023 | Oxlumo |
| Idorsia Pharmaceuticals US INC | $75.21 | 2023-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $74.70 | 2019-2021 | |
| Ibsa Pharma INC. | $69.10 | 2021-2023 | Tirosint, Licart |
| Biodelivery Sciences International, INC. | $68.42 | 2019-2021 | |
| Daiichi Sankyo INC. | $59.41 | 2019 | |
| Lilly USA, LLC | $57.86 | 2019-2020 | |
| Valinor Pharma, LLC | $56.87 | 2023-2025 | Movantik |
| Biotronik Nro, INC. | $55.02 | 2025 | Prospera |
| Allergan, INC. | $53.47 | 2020 | |
| Fidia Pharma USA INC. | $46.17 | 2020-2021 | |
| Hikma Pharmaceuticals USA | $42.36 | 2022 | |
| Eisai INC. | $42.12 | 2020 | |
| Spr Therapeutics, INC | $36.02 | 2023-2024 | Sprint Pns System |
| Curonix LLC | $30.75 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Indivior INC. | $30.72 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $30.67 | 2019 | |
| Avanos Medical | $28.32 | 2023-2025 | Generator, Standard Rf Disposables |
| Mdd US Operations, LLC | $26.94 | 2019-2020 | |
| Bioventus LLC | $25.82 | 2020 | |
| Medtronic USA, INC. | $24.18 | 2019 | |
| Mindray Ds USA, INC. | $23.71 | 2023 | Te X, Te7 Max |
| Hydrocision, INC. | $21.29 | 2022 | |
| Vertiflex, INC. | $19.00 | 2019 | |
| Tonix Medicines, INC. | $18.37 | 2025 | Tonmya |
| Pernix Therapeutics Holdings, INC. | $17.45 | 2019 | |
| Medtronic, INC. | $16.07 | 2024 | Intellis Adaptivestim |
| Depuy Synthes Sales INC. | $15.18 | 2019 | |
| Aytu Biopharma, INC. | $15.12 | 2020 | |
| Spinal Simplicity, LLC | $14.71 | 2025 | Ha Minuteman G3-R |
| Baudax Bio INC. | $14.53 | 2021 | |
| West Therapeutics Development, LLC | $14.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.36 | 2019 | |
| Djo, LLC | $13.80 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.43 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.52 | 2021 | |
| Tactile Systems Technology INC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Dirnberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.